CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6272 result(s)

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: January 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: Initial

luspatercept (Reblozyl)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.
  • Project Number: SR0669-000
  • Project Status: Active
  • Submission Type: Initial

liraglutide (Saxenda)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Active
  • Submission Type: Initial

Levetiracetam (pdp-levETIRAcetam)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Levetiracetam
Indications: Adjunctive therapy for: Adults management of patients with epilepsy who are not satisfactorily controlled by conventional therapyPediatrics partial onset seizures with or without secondary generalization in adolescents, children and infants from 1 month of age with epilepsy. myoclonic seizures in adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. primary generalized tonic-clonic seizures in adolescents from 12 years of age with Idiopathic Generalized Epilepsy.

  • Brand Name: pdp-levETIRAcetam
  • Manufacturer: Pendopharm, a division of Pharmascience Inc.
  • Project Number: SR0653-000
  • Project Status: Active
  • Submission Type: Initial

onasemnogene abeparvovec (Zolgensma)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: onasemnogene abeparvovec
Indications: ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: Initial

voretigene neparvovec (Luxturna)

Last Updated: December 17, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: voretigene neparvovec
Indications: ​Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

  • Brand Name: Luxturna
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0643-000
  • Project Status: Complete
  • Submission Type: Initial

brexucabtagene autoleucel (TBC)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: brexucabtagene autoleucel
Indications: For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi).

  • Brand Name: TBC
  • Manufacturer: Gilead Sciences Canada Inc.
  • Project Number: PG0219-000
  • Project Status: Active
  • Submission Type: Initial

budesonide (Jorveza )

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

vedolizumab (Entyvio)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0647-000
  • Project Status: Active
  • Submission Type: Initial

dapagliflozin (Forxiga )

Last Updated: January 6, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dapagliflozin
Indications: ​Forxiga is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit, and to improve heart failure symptoms.

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Active
  • Submission Type: Initial